Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,294,234
  • Shares Outstanding, K 77,275
  • Annual Sales, $ 0 K
  • Annual Income, $ -234,330 K
  • EBIT $ -318 M
  • EBITDA $ -316 M
  • 60-Month Beta 0.96
  • Price/Sales 448.11
  • Price/Cash Flow N/A
  • Price/Book 5.86

Options Overview Details

View History
  • Implied Volatility 155.40% (+7.19%)
  • Historical Volatility 34.88%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 155.40% on 02/11/26
  • IV Low 35.42% on 05/21/25
  • Expected Move (DTE 9) 4.34 (10.14%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 16
  • Volume Avg (30-Day) 1,902
  • Put/Call OI Ratio 1.23
  • Today's Open Interest 28,473
  • Open Int (30-Day) 25,930
  • Expected Range 38.43 to 47.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 9
  • High Estimate -0.99
  • Low Estimate -1.28
  • Prior Year -0.84
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.29 +8.83%
on 01/20/26
43.70 -2.15%
on 01/27/26
+0.61 (+1.45%)
since 01/09/26
3-Month
39.04 +9.53%
on 11/13/25
46.60 -8.24%
on 12/08/25
+2.84 (+7.11%)
since 11/11/25
52-Week
26.74 +59.91%
on 04/09/25
46.60 -8.24%
on 12/08/25
+4.37 (+11.38%)
since 02/11/25

Most Recent Stories

More News
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 42.76 (+0.30%)
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026 Five additional Phase 3 azetukalner studies continuing to enroll patients in...

XENE : 42.76 (+0.30%)
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 42.76 (+0.30%)
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedom New X-TOLE OLE data analysis supports the ability...

XENE : 42.76 (+0.30%)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 42.76 (+0.30%)
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 42.76 (+0.30%)
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight...

XENE : 42.76 (+0.30%)
Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 42.76 (+0.30%)
Xenon Pharmaceuticals: Q3 Earnings Snapshot

Xenon Pharmaceuticals: Q3 Earnings Snapshot

XENE : 42.76 (+0.30%)
Xenon Reports Third Quarter 2025 Financial Results & Business Update

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to...

XENE : 42.76 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 46.05
2nd Resistance Point 44.59
1st Resistance Point 43.67
Last Price 42.76
1st Support Level 41.29
2nd Support Level 39.83
3rd Support Level 38.91

See More

52-Week High 46.60
Last Price 42.76
Fibonacci 61.8% 39.01
Fibonacci 50% 36.67
Fibonacci 38.2% 34.33
52-Week Low 26.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar